The invention relates to a process for preparation of the compound 3-methyl-5-benzyloxy-2-(4-benzyloxyphenyl)-1H-indole 5, an intermediate for the synthesis of bazedoxifene and bazedoxifene acetate. ##STR00001##

Provided is an electrochromic compound represented by the following general formula (I) or (II) where R.sub.1 to R.sub.13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and at least one of the R.sub.1 to the R.sub.13 is a polymerizable functional group.

##STR00001##

Provided is an electrochromic compound represented by the following general formula (I) or (II) where R.sub.1 to R.sub.13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and at least one of the R.sub.1 to the R.sub.13 is a polymerizable functional group.

##STR00001##

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERR) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. ##STR00001##

The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. ##STR00001##

Provided is an electrochromic compound represented by the following general formula (I) or (II) where R.sub.1 to R.sub.13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and at least one of the R.sub.1 to the R.sub.13 is a polymerizable functional group.

Provided is an electrochromic compound represented by the following general formula (I) or (II) where R.sub.1 to R.sub.13 are each independently a hydrogen atom, a halogen atom, a monovalent organic group, or a polymerizable functional group, and at least one of the R.sub.1 to the R.sub.13 is a polymerizable functional group.

The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a -amino--biphenyl--methylalkanoic acid, or acid ester, backbone.